<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000813766">
  <TermName>Ojjaara</TermName>
  <TermPronunciation>(oh-JAR-uh)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A drug used to treat intermediate-risk or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF, in adults with anemia. Ojjaara blocks JAK and other proteins, which may help keep abnormal blood cells or cancer cells from growing. It is a type of kinase inhibitor. Also called momelotinib dihydrochloride monohydrate.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000814919" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Ojjaara&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000814920" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Ojjaara&quot;" language="es" id="_4"/>
  <SpanishTermName>Ojjaara</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Medicamento que se usa para el tratamiento de la mielofibrosis de riesgo intermedio o alto, incluso la mielofibrosis primaria, la mielofibrosis pospolicitemia vera y la mielofibrosis postrombocitemia esencial, en adultos con anemia. Ojjaara bloquea JAK y otras proteínas, lo que quizás ayude a evitar la multiplicación de células sanguíneas anormales o células cancerosas. Es un tipo de inhibidor de cinasas. También se llama monohidrato de diclorhidrato de momelotinib.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2023-09-22</DateFirstPublished>
  <RelatedInformation>
    <RelatedDrugSummaryRef UseWith="en" href="CDR0000813846" url="/about-cancer/treatment/drugs/momelotinib-dihydrochloride-monohydrate">Momelotinib Dihydrochloride Monohydrate</RelatedDrugSummaryRef>
  </RelatedInformation>
</GlossaryTerm>
